Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma
Christos Emmanouilides; Thomas E. Witzig; Gregory A. Wiseman; Leo I. Gordon; Hua Wang; Russell Schilder; M. Wayne Saville; Ian Flinn; Arturo Molina (Profiled Author: Leo I Gordon)
Cancer Biotherapy and Radiopharmaceuticals. 2007;22(5):684-691.Abstract
Objective: Treatment-related complications are more common in older patients with non-Hodgkin's lymphoma (NHL), often leading to chemotherapy modifications that can compromise efficacy. We analyzed data from clinical trials of yttrium-90-ibritumomab tiuxetan (Zevalin®; Biogen Idec, Cambridge, MA) to determine its safety and efficacy in older patients with NHL. Design and Methods: Data on safety and efficacy from four clinical trials of 90Y-ibritumomab tiuxetan in 211 patients with NHL were pooled and analyzed by ages of <60, 60-69, and ≥70 years. Results: Patients ≥70 years had a similar incidence of grade 3 or 4 neutropenia (68% vs. 66%), thrombocytopenia (68% vs. 70%), anemia (8% vs. 22%), and nonhematologic adverse events (23% vs. 19%) as that observed in patients <60 years. Response rates (range, 71%-80%) and the durations of response (median of 9.9, 11.0, and 9.4 months) were similar in the three groups. Conclusions: Yttrium-90-ibritumomab tiuxetan produces high rates of clinical response (up to 80%) and durable remissions in patients with NHL, and can be given at standard doses in older patients. The favorable safety profile of the regimen makes it an effective treatment for older patients, who may not otherwise tolerate the adverse events associated with chemotherapy. © Mary Ann Liebert, Inc. 2007.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Thomas E. Witzig; Christine A. White; Leo I. Gordon; Gregory A. Wiseman; Christos Emmanouilides; James L. Murray; John Lister; Pratik S. MultaniJournal of Clinical Oncology. 2003;21(7):1263-1270.
Stewart M. SpiesSeminars in Nuclear Medicine. 2004;34(1 SUPPL.1):10-13.
Gregory A. Wiseman; Peter S. Conti; Katie Vo; Russell J. Schilder; Leo I. Gordon; Christos Emmanouilides; Dan H. Silverman; Thomas E. Witzig; Mohamed Darif; et al.Clinical Lymphoma and Myeloma. 2007;7(8):514-517.
Appears in this Document